Summarised..

$Virpax Pharmaceuticals (VRPX.US)$ On November 19, 2024, Virpax Pharmaceuticals received a Nasdaq notification regarding non-compliance due to Dr. Eric Floyd's resignation. The company appointed Ms. Esha Randhawa as an independent director and Audit Committee member, regaining compliance with Nasdaq's requirements.Additionally, Virpax entered into an Independent Contractor Agreement with CEO Jatinder Dhaliwal, effective October 6, 2024. The agreement includes an annual fee of $200,000 and milestone-based incentives for advancing drug development programs.On November 21, 2024, Virpax announced an agreement with the U.S. Department of Health and Human Services to extend NES100 development for non-cancer pain management. The company also reported positive results for Probudur™ in a swine model study on November 22, 2024.